{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-293760","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2021-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.112488+00:00","generated_at":"2026-06-28T22:14:01.593297+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acumen doses first patient in Phase 1 trial of ACU193 for early Alzheimer's","bullets":["First patient dosed in INTERCEPT-AD Phase 1 trial of ACU193 for early Alzheimer's disease.","ACU193 is the first monoclonal antibody selectively targeting toxic amyloid-beta oligomers (AβOs).","Trial is placebo-controlled, single- and multiple-dose; enrollment ongoing.","CEO Daniel O'Connell: ACU193 has distinct potential to address unmet needs in Alzheimer's."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-293760","json":"https://secwatch.observer/filing/0001193125-21-293760.json","markdown":"https://secwatch.observer/filing/0001193125-21-293760.md","text":"https://secwatch.observer/filing/0001193125-21-293760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312521293760/0001193125-21-293760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312521293760/d208321d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T22:14:01.593297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}